Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Alimera, Allogene, Astrazeneca, Biocryst, Epimab, Gannex, Harbour, Immunocore, Immunovant, Karyopharm, Novavax, Oryzon, Passage, Regeneron, Roche, Scynexis, Sonoma, Sumitomo, Vertex.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: ABL, Acacia, Aurigene, Biocryst, Coave, Curevac, Curia, Dynamics, Eagle, Exavir, Ferring, Filament, Frame, Horama, Hoth, I-Mab, Integral, Jaguar, Olema, Optimeos, Panavance, Pfizer, Pint, Replicate, Reviral, Seelos, Senti, Tonix, Ziphius .

Clinical updates, including trial initiations, enrollment status and data readouts and publications: AB Science, Astrazeneca, Bicycle, Crinetics, DBV, Fibrogen, HMNC, Innovent, Marinus, Medicinova, Moderna, Neurelis, Precision, Prometheus, Promontory, Rigel, Sagimet, Sellas, Talaris, Tevogen.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Alvotech, Anavex, Emergent, Imaginab, Implant, J&J, Kadimastem, Lead, Multitude, Neurotrauma, Nosopharm, Oaktree, Oryzon, Oncusp, Oxeltix, Oxurion, Pfizer, Resverlogix, Roche, Stealth, Scisparc, and Targimmune, Tiziana, Vincerx.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Allovir, Annexon, Apellis, Concert, Eli Lilly, Engrail, GSK, Kazia, Merck, Moderna, Nascent, Newron, Ridgeback, Seres, Sobi.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Acer, Amgen, Antengene, Aum, Biocryst, Biondvax, BMS, Clarity, Cstone, Enlivex, GBT, Iaso, Innovent, Lexaria, Pfizer, Revive, Senhwa, Sensorion, Sifi, Veru.

Even as new waves of COVID-19 cause less direct disruption in the delivery of health care, the ongoing pandemic leaves a dramatically altered landscape for medical devices in its wake. The RBC Global Healthcare Conference revealed trends that will continue to reshape the utilization of medical technology and delivery of health care, while industry leaders drilled down into the details in a focused panel discussion. All agreed: the pandemic catapulted telemedicine and remote monitoring ahead five or more years, a hybrid delivery system with greater fluctuations in volume will emerge, devices that facilitate the movement of care out of the hospital to home or outpatient settings will remain in high demand and patient-centered control of health care will continue to attract additional industries into health care markets.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Acelyrin, Affibody, Alx, Aurinia, Biogen, Biothera, Incannex, Inmagene, Intercept, Merck, Nicox, Novo Nordisk, Olix, Sorrento, Tranquis.